Tema Oncology ETF Rating $28.32 +0.07 (+0.25%) (As of 09/27/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrends Tema Oncology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy2.79Holdings in CANC have an aggregate rating of Moderate Buy based on 531 analyst ratings issued in the past year covering 42 companies (82.8% of the portfolio).CANC Aggregate Price Target$42.3849.65% UpsideHigh Prediction$55.69Average Prediction$42.38Low Prediction$29.01Holdings in CANC have an aggregate price target of $42.38 and a range of $29.01 to $55.69 covering 42 companies (82.8% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy13 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 42 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.01%REGNRegeneron Pharmaceuticals$1,042.69+0.3%4.3658 of 5 stars2.77$1,118.62 7.3%22Analyst Forecast4.34%AMGNAmgen$322.67+1.1%4.3647 of 5 stars2.50$325.55 0.9%24Analyst ForecastShort Interest ↑4.25%MRKMerck & Co., Inc.$113.69+0.5%4.9846 of 5 stars2.93$134.58 18.4%15Analyst Revision3.91%ARGXargenx$536.11+2.2%1.8657 of 5 stars2.91$547.74 2.2%22Analyst ForecastShort Interest ↑News Coverage3.28%ILMNIllumina$130.12-1.6%4.5496 of 5 stars2.57$151.05 16.1%23Short Interest ↑3.27%RVMDRevolution Medicines$44.17+0.7%3.9429 of 5 stars3.09$53.45 21.0%11Analyst ForecastPositive News3.22%GILDGilead Sciences$83.61+0.7%4.7113 of 5 stars2.45$82.06 -1.9%20Analyst Revision3.13%BPMCBlueprint Medicines$92.55+3.9%3.6254 of 5 stars2.74$120.00 29.7%19Short Interest ↓Positive News2.76%INCYIncyte$65.83+1.1%4.855 of 5 stars2.32$73.24 11.2%19Short Interest ↓2.65%MREOMereo BioPharma Group$4.14+1.0%3.0974 of 5 stars3.20$7.50 81.2%5Positive News2.51%BGNEBeiGene$218.42+2.8%1.9833 of 5 stars2.71$241.21 10.4%7Short Interest ↓News CoverageGap Up2.51%NTLAIntellia Therapeutics$21.00+2.1%4.0934 of 5 stars2.80$61.77 194.1%15Gap Up2.36%LEGNLegend Biotech$49.27+5.2%3.0091 of 5 stars3.00$81.78 66.0%13Analyst ForecastNews CoveragePositive News2.30%CLDXCelldex Therapeutics$33.20+1.0%1.6025 of 5 stars3.00$63.83 92.3%7Analyst ForecastNews CoverageGap Down2.24%CRSPCRISPR Therapeutics$47.32+1.8%2.4873 of 5 stars2.37$75.63 59.8%192.17%GMABGenmab A/S$24.33+0.9%4.6666 of 5 stars2.46$45.20 85.8%13Gap Down2.13%AGIOAgios Pharmaceuticals$45.61-5.1%2.897 of 5 stars2.40$52.50 15.1%5Analyst DowngradeNews CoverageGap DownHigh Trading Volume2.11%EXELExelixis$25.96-1.1%4.4554 of 5 stars2.67$27.67 6.6%15Analyst ForecastInsider SellingShort Interest ↑2.01%EXASExact Sciences$65.96-2.9%4.3438 of 5 stars2.94$78.14 18.5%16Analyst ForecastShort Interest ↑Positive News1.80%NUVLNuvalent$99.10-1.9%2.8906 of 5 stars2.92$111.00 12.0%12Insider Selling1.80%ACLXArcellx$82.76-1.6%1.071 of 5 stars3.07$78.00 -5.8%15Short Interest ↓1.75%DAWNDay One Biopharmaceuticals$14.16-0.9%2.7422 of 5 stars2.88$35.71 152.2%8Short Interest ↑1.71%GHGuardant Health$22.88+0.7%4.4761 of 5 stars2.94$39.31 71.8%17News CoveragePositive News1.50%SWTXSpringWorks Therapeutics$32.280.0%1.6807 of 5 stars3.00$68.50 112.2%6Positive News1.49%LNTHLantheus$107.36+2.8%4.8456 of 5 stars2.89$126.00 17.4%9Positive News1.30%RCUSArcus Biosciences$15.41+0.1%2.1619 of 5 stars3.13$35.71 131.8%81.30%JANXJanux Therapeutics$46.25-0.8%3.7563 of 5 stars2.89$66.13 43.0%9Positive News1.29%MRUSMerus$47.74+1.2%2.2925 of 5 stars3.17$80.20 68.0%12Positive News1.19%CRBPCorbus Pharmaceuticals$20.92-2.7%4.7623 of 5 stars3.13$65.86 214.8%8Insider Buying1.15%SDGRSchrödinger$18.74-1.0%1.7983 of 5 stars2.80$33.44 78.5%101.14%MRNAModerna$65.75+2.8%4.5544 of 5 stars2.11$100.44 52.8%191.07%IDYAIDEAYA Biosciences$30.80+1.0%4.2732 of 5 stars3.08$56.00 81.8%13Analyst ForecastAnalyst RevisionNews Coverage0.98%COGTCogent Biosciences$10.903.1364 of 5 stars2.71$15.00 37.6%7Analyst ForecastShort Interest ↓Positive News0.94%BCYCBicycle Therapeutics$23.21-0.5%2.9943 of 5 stars2.78$44.56 92.0%9Short Interest ↑0.90%CGEMCullinan Therapeutics$17.19-0.6%1.9468 of 5 stars3.00$32.00 86.2%60.87%RLAYRelay Therapeutics$7.46+0.8%3.3974 of 5 stars2.90$21.11 183.0%10High Trading Volume0.76%TERNTerns Pharmaceuticals$8.55-3.4%4.4069 of 5 stars2.80$15.90 86.0%5Short Interest ↑0.67%ARVNArvinas$24.74+1.6%2.8693 of 5 stars2.88$57.50 132.4%160.66%IMCRImmunocore$31.40+2.0%2.6446 of 5 stars2.92$80.40 156.1%120.51%CGONCG Oncology$37.87+3.0%2.2608 of 5 stars3.13$64.43 70.1%80.50%JSPRJasper Therapeutics$18.83-0.1%3.7918 of 5 stars3.00$73.00 287.7%10Analyst ForecastNews Coverage0.40%FATEFate Therapeutics$3.57+2.0%4.2911 of 5 stars2.25$6.90 93.3%12 This page (NASDAQ:CANC) was last updated on 9/27/2024 by MarketBeat.com Staff From Our Partners10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredPrepare for an election day stock surpriseDuring his 50 years on Wall Street, legendary stockpicker Marc Chaikin traded through 13 presidential election...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANC Stock Alerts